Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Growth in Short Interest

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totalling 680,800 shares, an increase of 300.2% from the December 15th total of 170,100 shares. Based on an average trading volume of 348,300 shares, the short-interest ratio is currently 2.0 days. Approximately 1.0% of the shares of the company are short sold.

Tiziana Life Sciences Stock Down 10.2 %

NASDAQ TLSA traded down $0.09 during trading hours on Monday, hitting $0.75. The company had a trading volume of 395,438 shares, compared to its average volume of 486,784. Tiziana Life Sciences has a 52 week low of $0.41 and a 52 week high of $1.74. The firm has a 50 day simple moving average of $0.88 and a 200 day simple moving average of $0.95.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Tiziana Life Sciences stock. Zhang Financial LLC boosted its holdings in shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 24.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 69,387 shares of the company’s stock after buying an additional 13,500 shares during the period. Zhang Financial LLC owned approximately 0.07% of Tiziana Life Sciences worth $67,000 as of its most recent SEC filing.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.